Cue Biopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
Cue Biopharma, Inc. (CUE) filed a Current Report on Form 8-K on September 20, 2026. The filing discloses positive topline results from a Phase 2 clinical trial of its investigational drug CUE-221 for the treatment of Chronic Spontaneous Urticaria (CSU). The study was conducted in China by Genesis Life Sciences, an affiliate of Ascendant Health Ltd.
Key Clinical Metrics and Results
The filing does not provide financial metrics such as revenue, profit, cash flow, or debt, as this is a clinical update. Key clinical data points include:
- Study Design: Multicenter, randomized, double-blind, placebo and active comparator-controlled study with 145 participants.
- Primary Endpoint (HSS7=0 at Week 12): Met at all dose levels with dose-response observed.
- 4 mg/kg: 54% (p < 0.005 vs. placebo)
- 2 mg/kg: 53% (p < 0.005 vs. placebo)
- 1 mg/kg: 43% (p < 0.05 vs. placebo)
- Placebo: 11%
- Omalizumab (Active Comparator): 41%
- Key Secondary Endpoint (UAS7=0 at Week 12): Met statistical significance at the 4 mg/kg dose level (46% vs. 11% placebo).
- 4 mg/kg: 46% (p < 0.05 vs. placebo)
- 2 mg/kg: 39%
- 1 mg/kg: 38%
- Omalizumab: 29%
- Durability: At the 4 mg/kg dose, 60% of patients maintained complete resolution of hives 12 weeks after the last dose (Week 28), a statistically significant difference compared to omalizumab (24%).
- Safety: Favorable profile with no treatment-related serious adverse events, no anaphylaxis, and infrequent injection site reactions.
Material Changes and Outlook
The positive results represent a significant milestone for the CUE-221 program. Management commentary indicates the following next steps:
- CSU Development: The Company intends to initiate a Phase 2b/3 trial in CSU, subject to FDA review of the Phase 2 data.
- Food Allergy Development: An Investigational New Drug (IND) application has been submitted to the FDA for food allergy. The Company plans to initiate a Phase 2 trial in this indication.
- Conference Call: A call to discuss the data was scheduled for September 21, 2026.
Investor Verification Checklist
- Verify the full statistical analysis plan and detailed safety data in the upcoming full clinical data presentation.
- Confirm the FDA's response to the IND application for food allergy and the timeline for the Phase 2b/3 CSU trial initiation.
- Review the specific terms of the collaboration with Genesis Life Sciences/Ascendant Health Ltd. regarding data rights and future development responsibilities.
- Assess the Company's cash runway and capital requirements to fund the planned Phase 2b/3 and Phase 2 trials, as no financial data is provided in this filing.